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SUMMARY
Background—Data on influenza illness rates with population denominators are needed to 
quantify overall morbidity and to prioritize public health intervention strategies.
Methods—The rates of influenza A(H1N1)pdm09 infection during pandemic phases were 
determined in a longitudinal community cohort study as part of an influenza vaccine study in a 
rural community of North India.
Results—During the 711 731 person-weeks of surveillance, a total of 1410/7571 (19%) febrile 
acute respiratory illness cases were positive for influenza. Of these, 749 (53%) were influenza 
A(H1N1)pdm09, 643 (46%) influenza B, and 18 (1%) influenza A (H3N2). The overall incidence 
rate of influenza-associated febrile acute respiratory illness was 128/1000 person-years. The 
incidence rates of influenza A(H1N1)pdm09 were high during both the pandemic phase (179/1000 
person-years; November 2009 to January 2010) and post-pandemic phase (156/1000 person-years; 
August to October 2010), with children <18 years of age being at the greatest risk of influenza 
infection in the community.
Conclusions—These findings provide important information for planning clinical and public 
health intervention strategies to mitigate the impact of influenza epidemics.
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1. Introduction
A novel pandemic strain of influenza virus, A(H1N1)pdm09, emerged in April 2009 and 
spread rapidly worldwide.1 Understanding the transmission dynamics and incidence of 
influenza, especially in resource-constrained countries, where different co-morbidities might 
lead to a different burden and epidemiology, are important factors in devising public health 
responses and mitigation strategies for pandemic influenza control.1,2
Serological surveys during the early part of the pandemic suggested that the majority of 
naive populations would be susceptible to A(H1N1)pdm09 infection.3 Indeed, several 
studies established a consistent pattern of higher rates of A(H1N1)pdm09 infection in 
school-aged children relative to younger adults, with the lowest rates observed in older 
adults.4–7 The majority of the serological approaches to estimate the incidence of influenza 
A(H1N1)pdm09 have used a non-cohort-based design by the testing of longitudinal paired 
sera from pre- and post-pandemic phases or a cross-sectional design where a cut-off 
threshold was established to estimate exposure and/or infection.5–7 These studies underscore 
the need to have better indicators for understanding the incidence rates (IRs) of an epidemic 
along with population denominators to quantify overall morbidity and to prioritize public 
health intervention strategies.2 Modeling studies may have an important role in early 
estimates of cumulative incidence; however, prospective cohort studies, such as the one 
described here, are needed to provide the actual community estimates of influenza incidence.
Population-based weekly active surveillance implemented soon after the emergence of 
pandemic influenza in a rural community in India8 provided an opportunity to determine the 
overall incidence of A(H1N1)pdm09 during the first influenza pandemic of the 21st century. 
This information on magnitude, age distribution, and seasonality of A(H1N1)pdm09 will be 
useful for modeling disease burden, advocacy, and health system planning.
2. Methods
2.1. Study population
During November 1, 2009 to October 31, 2010, all members of the households residing in 
three villages located in the Ballabhgarh sub-district of Faridabad, Haryana State in North 
India, were eligible to enroll in the febrile acute respiratory illness (FARI) surveillance 
component of an influenza vaccine trial of children aged 6 months to 10 years within the 
same villages.8 The vaccine trial is an ongoing prospective, longitudinal, phase IV, 
household-randomized, controlled, observer-blinded 3-year study (2009–2011) designed to 
measure the direct and indirect protective effects of immunizing children aged 6 months 
through 10 years with seasonal inactivated trivalent influenza vaccine (TIV) or a control 
vaccine (http://www.ClinicalTrials.gov, NCT00934245).8 The 2009 northern hemisphere 
influenza vaccine administered in December 2009 through January 2010 included strains: A/
Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and B/Brisbane/60/2008. Pandemic 
virus was not a component of this vaccine.
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Members of 2806 households (enrollment rate >90% of eligible cases) in the villages were 
enrolled in the FARI surveillance and received weekly home visits, represented as 
epidemiologic weeks (EW) throughout the year (no surveillance occurred in EW48 and 
EW53 of 2009 due to vaccination efforts). If a household member who was to be surveyed 
was not present at the time of the home visit by the study trained surveillance officer, proxy 
information about possible FARIs was collected from an available adult in the household. 
Possible FARI cases identified by the study surveillance officers were visited by nurses for 
confirmation of case definition, clinical assessment, and collection of specimens for 
influenza testing. The study population was a dynamic study cohort under weekly 
surveillance, with changes in the household composition (marriages/moves and births/
deaths) recorded in the study database as reported throughout the year.
Written informed consent was obtained from each household member for enrollment into 
the study. For children, consent from their parents was obtained, and where appropriate, 
assent from the child. Institutional review board approval was obtained from the All India 
Institute of Medical Sciences, New Delhi, India, the University of Alabama at Birmingham, 
Birmingham, and the Centers for Disease Control and Prevention, Atlanta.
2.2. Case definition
FARI was defined as a history (current or in the preceding week) of fever with any of the 
following respiratory complaints: cough, sore throat, congestion/runny nose, earache, or 
difficulty in breathing.
2.3. Specimen collection and influenza detection
For each FARI episode, combined throat and nasal swabs were collected from children ≥1 
year of age and adults, and nasopharyngeal swabs were collected from infants <1 year of 
age. US Centers for Disease Control and Prevention real-time RT-PCR protocols were used 
for the detection and subtyping of influenza viruses, as described previously.9
2.4. Data analysis
Clinical and demographic information on FARI cases was collected on paper forms at the 
weekly household visits. Laboratory results were linked to the FARI surveillance 
information in the study database. FARI IRs were calculated by taking the total number of 
FARI cases identified in the age-group for the numerator, and the total person-time 
contributed by individuals who were surveyed each week in the specific age-group for the 
denominator. The proportions of samples positive for each influenza subtype in each age 
group were calculated for each time period. This positive proportion was then applied to the 
FARI IRs to calculate the influenza IRs overall and by subtype. This yielded influenza IRs 
adjusted for FARI cases from whom either no respiratory tract samples were obtained or 
whose samples were inadequate for testing (unsampled cases). IRs and 95% confidence 
intervals (95% CI) were calculated for pandemic influenza. All statistical analyses were 
performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).
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3. Results
3.1. Incidence rates for FARI
The total study population under surveillance for at least 1 week during the 1-year study 
period was 18 220 individuals. The study included 14 229 individuals enrolled into the 
cohort at the beginning of the study, an additional 3991 individuals who enrolled during the 
course of the study, and 1359 cohort members who dropped out during the study year 
(withdrawals, deaths, and migrations). The final population under surveillance on October 
31, 2010 was 16 861 individuals. Overall, 9395 incident FARI episodes were recorded with 
711 731 person-weeks of observation completed (Table 1). Weekly surveillance of an 
average 13 687 household members over the year revealed two distinct peaks of FARI 
episodes (EW45–EW52 in 2009 and EW32–EW40 in 2010), although FARI cases occurred 
throughout the study period (Figure 1). Over 50% of the incident FARI episodes occurred in 
children aged 0–18 years, with 30% occurring in children 0–5 years of age. The overall IR 
for FARI was 686/1000 person-years. The FARI rate was highest in children 0–5 years of 
age (1672/1000 person-years), followed by children 6–18 years of age (657/1000 person-
years) (Table 2).
3.2. Incidence rates for A(H1N1)pdm09 influenza
A total of 81% of incident FARI (7571/9395) cases were tested for influenza. Among the 
FARI cases unavailable for influenza testing, 56% were adults (≥19 years) and 44% children 
(<19 years), and there was no difference in any of the demographic characteristics of those 
tested vs. not tested. Of the 7571 specimens tested, 1410 (19%) were positive for influenza. 
Of these, 749 (53%) were influenza A(H1N1)pdm09, 643 (46%) influenza B, and 18 (1%) 
influenza A (H3N2) (Table 1). There were two distinct peak periods of influenza positivity 
at EW45–EW52 (November–December) of 2009 and EW32–EW40 (August–October) of 
2010, with co-circulation of influenza B viruses throughout the study period (Figure 1). The 
first peak during the pandemic period was almost exclusively due to influenza 
A(H1N1)pdm09 virus. The IR for influenza A(H1N1)pdm09 was greatest during the first 
pandemic phase in November–December 2009 (179/1000 person-years), followed by a 
second peak in the post-pandemic phase in August–October 2010 (156/1000 person-years) 
(Figure 2; Table 1).
Age-wise distribution of pandemic A(H1N1)pdm09 revealed the greatest IR in children aged 
0–5 years (120/1000 person-years) and 6–18 years (93/1000 person-years) when compared 
with adults (Table 2). Children aged 0–5 years and 6–18 years were more likely to have 
A(H1N1)pdm09 (incidence rate ratio (IRR) 2.5, 95% CI 2.1–3.0; and IRR 1.9, 95% CI 1.7–
2.2, respectively) than adults aged 19 years and older, indicating that children aged 0–18 
years have the greatest IRs for pandemic influenza in the community.
4. Discussion
Understanding the incidence of pandemic influenza is important for devising public health 
responses and mitigation strategies for pandemic influenza control. Our study demonstrated 
high IRs of A(H1N1)pdm09 in the rural community during the peak pandemic and post-
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pandemic periods in the year following the emergence of pandemic influenza in North India. 
The IR of FARI estimated to be 686/1000 person-years using a population-based study in a 
rural village in North India, is at least 10 times higher than estimated influenza-like illness 
rates in a southern province of China.10 The difference in IRs may be explained partly by the 
survey methods (active population survey in the current study vs. multi-stage stratified 
cluster sampling in the latter) or the timing of the survey (current surveillance implemented 
during the pandemic in 2009 vs. 2007 in the China survey). Prospective analysis of FARI 
cases over the study period demonstrated circulation of both pandemic 2009A/H1N1 and 
influenza B (influenza A (H3N2) was limited) throughout the year. Additionally, pandemic 
2009A/H1N1 revealed atypical seasonality, with a peak in November–December 2009, 
whereas seasonal influenza peaks are typically observed in the monsoon season in the Delhi 
area.9
Another unique aspect of our study was the ability to determine IRs for pandemic 
A(H1N1)pdm09 during the pandemic and post-pandemic phases. Using the numbers of 
persons in the cohort as the denominator, the overall influenza A(H1N1)pdm09 incidence of 
6.8% for all age groups identified in our prospective cohort-based study is lower than the 
11% summary attack rate for all ages reported in a Hong Kong serosurvey5 and the 16–18% 
incidence observed in serosurveys in England.4 The difference in our cohort-based pandemic 
influenza incidence and the serosurvey-based rates may be due to the study definition (FARI 
case definition with laboratory confirmed infection vs. the presence of an antibody response 
indicating infection, subclinical infection, and/or cross-reactive antibodies), difference in 
study populations (rural vs. urban), or study design (prospective cohort-based vs. pre–post 
cohort design). Further we demonstrated that although the incidence of A(H1N1)pdm09 was 
highest during the late 2009 pandemic phase, comparable high rates were also observed 
during the post-pandemic period from August to October 2010.
In our study population, children (0–18 years) had significantly higher IRs of symptomatic 
A(H1N1)pdm09 influenza than adults. During the first wave of pandemic influenza, analysis 
of multiple published studies estimated influenza IRs to be 34–43% among school-aged 
children and 10% in adults in eight countries from four continents.7,11 Familial clustering 
studies have shown that influenza incidence is greater in children than in adults, and 
observational studies have shown that living with children increases the risk of influenza 
infection.7,11 Recent data suggest that the reduced incidence and severity of infection with 
A(H1N1)pdm09 virus in the adult population during the 2009–2010 influenza season may 
have been a result of previous exposure to seasonal influenza A viruses.12,13 Our results 
suggest that exposure to children should be taken into account for influenza research studies, 
especially for influenza vaccine efficacy trials in adults with known familial exposure to 
children.2
This study has several limitations. First, our use of self-reported fever in the FARI case 
definition may have captured a wide range of febrile illnesses and overestimated the 
incidence of true febrile respiratory illness. However, influenza incidence was not likely to 
be overestimated as the majority of the FARI incident cases were tested for influenza by 
molecular methods. Second, the overall influenza rates reported here may have been 
influenced by the fact that almost one-half of the children had received influenza vaccine 
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from November 2009 to January 2010.8 While the 2009 seasonal vaccine did not contain 
pandemic virus, recent studies have shown that prior infection with influenza A (H1N1),12,13 
or immunization with seasonal live attenuated influenza vaccine, may confer some cross-
protection against the A/(H1N1)pdm09 virus.14,15 Thus, we believe that the current study 
likely represents a minimal estimate of IRs for pandemic influenza. It is plausible that the 
true incidence of A(H1N1)pdm09 may even be greater than the IR we reported for the 
pandemic period, since the initial pandemic influenza peak was observed during August 
2009 in this region but was not captured because the study reported here had not yet begun.8
The results of this large-scale community-based household surveillance are important for 
quantifying influenza risk at the population level. These data can contribute to global efforts 
to estimate burden of seasonal and pandemic influenza, which are useful for advocacy for 
strengthening influenza prevention and control efforts. At a national level, such studies 
provide important information for planning clinical and public health intervention strategies 
to mitigate the impact of influenza epidemics.
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Figure 1. 
Weekly trend of influenza positivity during active surveillance in a community-based study 
from November 2009 to October 2010 in rural India. The left axis shows the number 
positive for seasonal influenza (red bar: A(H3N2); green bar: influenza B) and pandemic 
A(H1N1)pdm09 (blue); the total number of samples tested (line) is shown on the right axis. 
Children aged 6 months to 10 years received either trivalent seasonal influenza vaccine 
(intervention) or inactivated polio vaccine (control).10
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Figure 2. 
Incidence rate/1000 person-years for pandemic influenza A(H1N1)pdm09 in a rural 
community in North India during the pandemic phase (until July 2010) and post-pandemic 
phase (since August 2010). The incidence rates for A(H1N1)pdm09 were greatest during the 
first pandemic wave from November 2009 to January 2010 (179/1000 person-years), 
followed by a second peak in the post-pandemic phase in August–October 2010 (156/1000 
person-years), with very low rates observed (≥3/1000 person-years) during the inter-
pandemic period from February to July 2010.
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